Technology
Health
Biotechnology

Deciphera Pharmaceuticals

$23.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (0.81%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell DCPH and other stocks, options, ETFs, and crypto commission-free!

About

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. Read More It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Employees
114
Headquarters
Waltham, Massachusetts
Founded
2003
Market Cap
896.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
244.36K
High Today
$24.30
Low Today
$23.16
Open Price
$23.61
Volume
33.17K
52 Week High
$45.61
52 Week Low
$18.55

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2017 IPO
US
North America

News

Yahoo FinanceMay 9

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- - Top-line Data from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Fourth-line and Fourth-line Plus GIST Patients Expected in Mid-2019 - - Recommended Phase 2 Dose Selected for Part 2 of Phase 1b/2 Study of Rebastinib plus Paclitaxel; Enrollment in Part 2 with Expansion Cohorts Expected to Commence Second Quarter 2019 - - Ended First Quarter 2019 with Cash, Cash Equivalents and Marketable Securities of $262 Million - Deciphera Pharmaceuticals, Inc. (DCPH), a ...

23
Yahoo FinanceMay 4

Here’s What Hedge Funds Think About Deciphera Pharmaceuticals, Inc. (DCPH)

Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the future holds and how market participants will react to the bountiful news that floods in each day. Hedge funds underperform because they are hedged. The Standard and Poor’s 500 Index returned appr...

24

Earnings

-$5.85
-$4.05
-$2.26
-$0.46
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.